Dawn (Dan) Zhang

Shanghai Co-Managing Shareholder
Shanghai,  China
Phone+86 (0) 21 6391 6633

Peer Rating

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials

Practice Areas

  • Corporate & Securities
  • Mergers & Acquisitions
  • Private Equity
  • Life Sciences & Medical Technology
  • Franchise & Distribution
  • Foreign Corruption Practices Act (FCPA) & Global Anti-Corruption
Contact InfoTelephone: +86 (0) 21 6391 6633
Fax: +86 (0) 21 6391 6232
EducationFudan University School of Law (LL.B.); University of Pennsylvania Law School (LL.M.)
Admitted1998, PRC; 2005, New York
LanguagesChinese (Mandarin), Fluent; English, Fluent

Dawn (Dan) Zhang has broad experience advising clients on China-related cross-border mergers and acquisitions, restructuring, joint ventures, funds, and general corporate matters. Before joining Greenberg Traurig, Dawn practiced in other international law firms for many years and served as the PRC legal counsel for a multinational corporation, where she handled a wide variety of corporate matters for public and emerging growth companies. Dawn passed the national PRC judicial qualification examination in 1998 and is admitted to practice in New York.

Areas of Concentration

•Mergers and acquisitions
•Foreign direct investment
•Corporate governance and compliance
•Life sciences

Awards & Recognition

•Listed, Asian Legal Business, Top 15 Rising Lawyers, 2014

Associated News & Events

Press Releases

09.11.08 Greenberg Traurig's Shanghai Office Increases International Corporate & Securities Practice with Addition of Dawn Zhang


07.24.15 China Newsletter, Summer 2015 / No. 31
05.19.15 The GT M&A Report, Vol. 7 Ed. 1
04.29.15 China Newsletter, Spring 2015 / No. 30
02.12.15 Tencent vs. Qihoo - A Significant 2014 Anti-monopoly Ruling in China
02.12.15 Antitrust Quarterly, Winter 2015
01.20.15 China Newsletter, Winter 2015 / No. 29
12.08.14 The GT M&A Report, Vol. 6 Ed. 2
12.01.14 ICSID Arbitration Initiated Against China as Negotiations Move Ahead on U.S.-China Bilateral Investment Treaty
11.19.14 Life Sciences & Medical Technology Newsletter, Fall / Winter 2014
11.17.14 Anti-monopoly Probe and Enforcement in China - Paying the Price for Price!

Articles, Publications, & Lectures

•Presenter, Anti-Corruption Due Diligence, ALB In-House Summit, Shanghai, China, June 2014
•Co-Author, How to Do Due Diligence on Third Parties, China Law and Practice, January/February, 2014
•Co-Author, Managing FCPA Risks in PE, China Law and Practice, September/October, 2013
•Co-Presenter, How Your Company Can Benefit From China's Thirst for New Technology, Greenberg Traurig LLP and Burr Pilger Mayer seminar, Silicon Valley, CA, October 20, 2010
•Panelist, “Venture Capital and Private Equity in China” section of “The China Deal 2010: Legal and Economic Outlook for Inbound and Outbound Deals”, Thomson Reuters Group, San Francisco, CA, October 6, 2009
•Co-Presenter, “Uniquely Chinese - Technical Challenges to Litigating in China”, “Legal Challenges to Chinese Companies Doing Business in the United States,” American Bar Association, Tsinghua University, Beijing, China, September 10, 2009
•Co-Presenter, Legal Due Diligence in China - A Practical Guide, CCH Merger & Acquisition Conference, Shanghai, China, October 30th - 31st, 2008
•Presenter, Corporate Governance in China, PRC Corporate Governance Seminar, Singapore, January 11, 2007

Reported CasesSignificant Representations M&A and Joint Ventures;Assisted PRA in forming a CRO joint venture with Wuxi PharmaTech to carry out Phase I-IV clinical trial services in China.Assisted a global leader in business process and technology management in acquiring majority equity interest of a BPO service provider (under VIE structure) in Shanghai.Assisted a consulting firm in selling their equity interest in a HK company and its Shanghai WFOE to a world leading consulting firm.Acted as the primary lawyer in China to assist a leading OEM multinational corporation in acquiring a target company's notebook PC OEM business for US$ 200 million.Advised and assisted a leading U.S. automotive company in setting up in China an equity joint venture with a large PRC state-owned automotive company.Represented the world's largest contract manufacturer of wire formed medical devices and components in its strategic investment in a HK medical device company and its PRC subsidiaries.Conducted in-depth due diligence and handled transactional documents for a research laboratory company with US$ 3 billion in annual sales for its US$ 30 million strategic investment in a PRC medical device group.Represented a network infrastructure products and services provider in acquiring the equity interest of a PRC telecommunications equipment group for US$ 70 million.Represented a leading NYSE-listed building products manufacturer in restructuring of its BVI and PRC subsidiaries, and in acquisition of a household appliance factory in Huizhou, China. Funds;Acted as investor counsel in a US$20 million A round investment in a vaccine company in China.Acted as investor counsel in a US$ 60 million A round investment in a Nanjing pharmaceutical company.Acted as investor counsel in a US$ 10 million A round investment in an online underwear company in Guangzhou.Acted as investor counsel in a RMB 20 million A round investment in a health care management company in Beijing.Acted as company counsel of a media advertisement company in accepting investments from angel investors and VC investors.Advised as investor counsel on A and B rounds investment in a mining company.Acted as company counsel of a pharmaceutical company in Chengdu with a registered capital of US$ 50 million inn accepting investment from syndicate VC investors.Acted as company counsel in a RMB 35 million VC financing in a railway systems R&D company.Acted as company counsel of a Nantong company in a US$ 75 million Series A financing by syndicate investors. Corporate Governance and Compliance (FCPA);Provided trainings on FCPA and anti-bribery laws; assisted in developing and implementing corporate compliance program (FCPA); Created code of conduct. Others Areas of Concentration;Franchise and licensing;Industries include: life sciences (drugs, vaccines, medical devices, CROs, APIs, clinics, bio-engineering, health care, etc.), automobile, retailer, internet and emerging technology, manufacturing, etc.

Documents by this lawyer on Martindale.com

Subscribe to this feed

Tencent vs. Qihoo - A Significant 2014 Anti-monopoly Ruling in China
Cathy Zhang,Dawn (Dan) Zhang, February 24, 2015
After an almost two-year litigation marathon, the Supreme People’s Court of China (Supreme Court), in October 2014, upheld the ruling of the Guangdong High Court (High Court) that Tencent QQ did not abuse a market dominance position under the Anti-monopoly Law of People’s Republic of...

ICSID Arbitration Initiated Against China as Negotiations Move Ahead on U.S.-China Bilateral Investment Treaty
David Baron,Philippe M. Bruno,Owen D. Nee,Thomas R. Snider,Dawn (Dan) Zhang, February 17, 2015
Arbitration proceedings have been initiated against China for only the second time at the International Centre for Settlement of Investment Disputes (ICSID), an international arbitral institution that is a member of the World Bank Group. In this new case, a Korean company has reportedly brought an...
Profile Visibility
#21 in weekly profile views out of 1,456 lawyers in Shanghai, China
#110,987 in weekly profile views out of 1,739,582 total lawyers Overall

Office Information

Dawn (Dan) Zhang

Rooms 3125-3141, Shanghai Central Plaza, 381 Huai Hai Zhong Lu
Shanghai 200020

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now